Search
Estradiol dienanthate
go.drugbank.com/drugs/DB13955ApprovedVet approvedWithdrawnFirst-pass metabolism by the gut and the liver quickly degrades the estradiol molecule before it gets a chance to enter systemic circulation and exert its estrogenic effects [A12102]. … Estradiol is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).
Bebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigational[L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE. … [A7476,A7477] After the discovery of certain bacteria with the capacity to inactivate folate analogs such as methotrexate, carboxypeptidase G was identified and Carboxypeptidase G1 was first isolated
DL-Methylephedrine
go.drugbank.com/drugs/DB11278ApprovedThe abuse of methylephedrine-containing medications has been reported in Japan. Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].
Geraniol
go.drugbank.com/drugs/DB14183ApprovedThese pharmacologic effects are clinically important as geraniol is classified as generally-recognized-as-safe (GRAS) by the Flavor and Extract Manufacturers Association (FEMA) and the Food and Drug Administration … Geraniol has demonstrated a wide spectrum of pharmacological activities including antimicrobial, anti-inflammatory, antioxidant, anti-cancer, and neuroprotective to name a few [A34260,A34261,A34262].
Xenon Xe-129
go.drugbank.com/drugs/DB17386ApprovedInvestigationalLung MRIs are challenging due to the low proton density of this tissue, as well as the presence of artifacts due to respiration and cardiovascular pulsation movement and air–tissue interfaces. … [A255178] Xe-129 has a lower cost, and adverse effects are normally resolved shortly after administration.
Myrrh
go.drugbank.com/drugs/DB11605ApprovedInvestigationalExtractives and their physically modified derivatives such as tinctures, concretes, absolutes, essential oils, oleoresins, terpenes, terpene-free fractions, distillates, residues, obtained from Commiphora
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327] … [A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate.
Estrone sulfate
go.drugbank.com/drugs/DB04574ApprovedIt has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual … Estrone sulfate (as estropipate) is a form of estrogen.
Encorafenib
go.drugbank.com/drugs/DB11718ApprovedInvestigationalEncorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … Mutations in this gene, most frequently the V600E mutation, are the most commonly identified cancer-causing mutations in melanoma, and have been isolated in various other cancers as well, including non-Hodgkin